Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
Authors' conclusion
In this population, treatment with CSL112 compared to placebo was associated with a significantly lower risk of recurrent cardiovascular events among patients with a baseline LDL-C ≥ 100 mg/dL.
Study context
- Population
- Patients with acute myocardial infarction (MI), multivessel CAD and additional risk factors, prescribed guideline-directed statin therapy at randomisationof 18,219 randomized
- Participants
- 15,731 patients
- Comparison
- CSL112 vs placebo, by baseline low-density lipoprotein cholesterol (LDL-C)
- Primary endpoint
- Primary endpoint (as in AEGIS-II), by baseline LDL-C
- Follow-up
- 90 days
Methodological detailsexploratory post-hoc analysis
- Exploratory post-hoc analysis
Primary result
As reported in the abstract
CV death, MI or stroke, by baseline LDL-C (subgroups)
CSL112 vs PlaceboHazard ratio (CI)
LDL-C ≥ 100 mg/dL, 90 days
.69(.53-.90)
LDL-C ≥ 100 mg/dL, 180 days
.71(.57-.88)
LDL-C ≥ 100 mg/dL, 365 days
.78(.65-.93)
Original publication
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial. Eur Heart J. Published 2 September 2024. doi:10.
Summarised from the published abstract; every number is checked against it